Evidence map›Paper›PMID 32580032›Full record

ArticleContemporary clinical trials2020

Design of a cluster-randomized trial of the effectiveness and cost-effectiveness of metformin on prevention of type 2 diabetes among prediabetic Mexican adults (the PRuDENTE initiative of Mexico City).

Luis A Rodríguez, Simón Barquera, Carlos A Aguilar-Salinas, Jaime Sepúlveda-Amor, Luz María Sánchez-Romero, Edgar Denova-Gutiérrez, Nydia Balderas, Lizbeth Moreno-Loaeza, Margaret A Handley, Sanjay Basu and 3 more

Registry-linked trialOpen access · greenAbstract readClinical Trial Protocol
In one paragraph

Article in Contemporary clinical trials, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT03194009. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03194009 naunknown status

Public Healthcare Systems and Diabetes Prevention Among People of Mexican Origin: The PRuDENTE Initiative of Mexico City.

Ran2017Enrolled3,060Registered outcomes8Posted comparisons0ConditionsDiabetes Mellitus, Type 2, Prediabetic StateArmsLifestyle Intervention, Metformin
Open the trial in the graph
3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 2 countries.

Luis A RodríguezDepartment of Epidemiology & Biostatistics, University of California, San Francisco, San Francisco, CA, USA. Electronic address: Luis.Rodriguez@ucsf.edu.
Simón BarqueraNutrition and Health Research Center, National Institute of Public Health, Cuernavaca, Mexico.
Carlos A Aguilar-SalinasDivision of Nutrition, Salvador Zubiran National Institute of Medical Sciences and Nutrition, Mexico City, Mexico.
Jaime Sepúlveda-AmorDepartment of Epidemiology & Biostatistics, University of California, San Francisco, San Francisco, CA, USA; Institute for Global Health Sciences, University of California, San Francisco, San Francisco, CA, USA.
Luz María Sánchez-RomeroNutrition and Health Research Center, National Institute of Public Health, Cuernavaca, Mexico.
Edgar Denova-GutiérrezNutrition and Health Research Center, National Institute of Public Health, Cuernavaca, Mexico.
Nydia BalderasNutrition and Health Research Center, National Institute of Public Health, Cuernavaca, Mexico.
Lizbeth Moreno-LoaezaResearch Unit on Metabolic Diseases, Salvador Zubiran National Institute of Medical Sciences and Nutrition, Mexico City, Mexico; Medical, Dental and Health Sciences, National Autonomous University of Mexico, Mexico City, Mexico.
Margaret A HandleyDepartment of Epidemiology & Biostatistics, University of California, San Francisco, San Francisco, CA, USA; Division of General Internal Medicine at San Francisco General Hospital, University of California, San Francisco, San Francisco, CA, USA; UCSF Center for Vulnerable Populations, San Francisco General Hospital, San Francisco, CA, USA.
Sanjay BasuDepartment of Medicine, Stanford University, Palo Alto, CA, USA.
Oliva López-ArellanoMinistry of Health, Mexico City, Mexico.
Alberto Gallardo-HernándezMinistry of Health, Mexico City, Mexico.
Dean SchillingerDivision of General Internal Medicine at San Francisco General Hospital, University of California, San Francisco, San Francisco, CA, USA; UCSF Center for Vulnerable Populations, San Francisco General Hospital, San Francisco, CA, USA.
Instituto Nacional de Salud Pública · MXUniversity of California, San Francisco · USInstituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán · MXSan Francisco General Hospital · USStanford University · USTecnológico Nacional de México · MX

Funding

ZIDOVUDINE &LAMIVUDINE &NEVIRAPINE COMBINATION THERAPY IN HIV 1 INFM01RR001271 · NCRR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KESSLER, DAVID A · 1985 to 2006
$22.7M
UCSF Nutrition Obesity Research CenterP30DK098722 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHRISTIAN VAISSE · 2015 to 2026
$14.6M
Translational Research Core - Health Engagement & Action Translational (HEAT)P30DK092924 · NIDDK · KAISER FOUNDATION RESEARCH INSTITUTE · PI Alyce Sophia Adams, HILARY Kessler SELIGMAN · 2011 to 2026
$9.2M
Testing combinations of population interventions to encourage healthy eatingR01DK116852 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SCHILLINGER, DEAN · 2018 to 2022
$3.7M
Race/Ethnic Specific Association Between Anthropometry, Liver Fat and Incident Type 2 Diabetes: Evidence from The Multi-Ethnic Study of AtherosclerosisF31DK115029 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI RODRIGUEZ, LUIS A · 2018 to 2020
$102k
NCRR NIH HHS M01 RR001271NIDDK NIH HHS F31 DK115029NIDDK NIH HHS P30 DK092924NIDDK NIH HHS P30 DK098722NIDDK NIH HHS R01 DK116852
6 · The paper itself

Abstract

introductionType 2 diabetes (T2D) is a global epidemic, and nations are struggling to implement effective healthcare strategies to reduce the burden. While efficacy studies demonstrate that metformin can reduce incident T2D by half among younger, obese adults with prediabetes, its real-world effectiveness are understudied, and its use for T2D prevention in primary care is low. We describe the design of a pragmatic trial to evaluate the incremental effectiveness of metformin, as an adjunct to a simple lifestyle counseling.

methodsThe "Prevención de la Diabetes con Ejercicio, Nutrición y Tratamiento" [Diabetes Prevention with Exercise, Nutrition and Treatment; PRuDENTE, (Spanish acronym)] is a cluster-randomized trial in Mexico City's public primary healthcare system. The study randomly assigns 51 clinics to deliver one of two interventions for 36 months: 1) lifestyle only; 2) lifestyle plus metformin, to 3060 patients ages 30-65 with impaired fasting glucose and obesity. The primary endpoint is incident T2D (fasting glucose ≥126 mg/dL, or HbA1c ≥6.5%). We will also measure a range of implementation-related process outcomes at the clinic-, clinician- and patient-levels to inform interpretations of effectiveness and enable efforts to refine, adapt, adopt and disseminate the model. We will also estimate the cost-effectiveness of metformin as an adjunct to lifestyle counseling in Mexico. DISCUSSION: Findings from this pragmatic trial will generate new translational knowledge in Mexico and beyond, both with respect to metformin's real-world effectiveness among an 'at-risk' population, and uncovering facilitators and barriers to the reach, adoption and implementation of metformin preventive therapy in public primary care settings.

trial registrationThis trial is registered at Clinicaltrials.gov (NCT03194009).

Indexed as

Diabetes Mellitus, Type 2MetforminPrediabetic StateAdultAgedCost-Benefit AnalysisHumansMexicoMiddle AgedPragmatic Clinical Trials as TopicRandomized Controlled Trials as TopicMetforminCluster trialImplementation evaluationMetforminMexicoResearch protocolType 2 diabetes

Identifiers

PMID32580032
PMCPMC7484103
OpenAlexW3035851570

What OpenQuestion holds

Texttitle and abstract
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.